Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patriarca

Showing results (921-930 of 1,012) with videos related to

Pageof 102
Sort By:
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|November 25, 2022
Perspectives in linear accelerator for FLASH VHEE: Study of a compact C-band systemL Faillace, D Alesini, G Bisogni, et al.
Leukemia|March 10, 2026
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini, et al.
Transplantation and Cellular Therapy|April 6, 2024
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeMirko Farina, Maria Chiara Scaini, Antonella Facchinetti, et al.
Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Blood Advances|August 20, 2020
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-CyJacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.
Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Neuro-Oncology|November 2, 2020
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-upMaura Massimino, Francesco Barretta, Piergiorgio Modena, et al.
Pageof 102

Showing results (921-930 of 1,012) with videos related to

Sort By:
Pageof 102
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|November 25, 2022
Perspectives in linear accelerator for FLASH VHEE: Study of a compact C-band systemL Faillace, D Alesini, G Bisogni, et al.
Leukemia|March 10, 2026
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini, et al.
Transplantation and Cellular Therapy|April 6, 2024
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeMirko Farina, Maria Chiara Scaini, Antonella Facchinetti, et al.
Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Blood Advances|August 20, 2020
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-CyJacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.
Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Neuro-Oncology|November 2, 2020
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-upMaura Massimino, Francesco Barretta, Piergiorgio Modena, et al.
Pageof 102